J. Gregory Swendsen is President of Swendsen & Company, a financial management company founded in 1984 that specializes in seed and venture capital in the life sciences and applied technologies. Mr. Swendsen is a founder of SuperGen, Inc., a leading developer of anti-cancer drugs, a founder of Quark Pharmaceuticals, Inc., which was aquired by SBI Biotech in 2012, and served on the board of AMUR Pharmaceuticals prior to its sale to SuperGen. In July 2011 SuperGen acquired Astex Pharmaceuticals, Inc. In October 2013 Astex was aquired by Otsuko Holdings Co. for $886 million. Mr. Swendsen currently sits on the board of American Life Science Pharmaceuticals, Inc., a clinical stage Alzheimer's and neurodegenerative disease company, and was an early investor in NovaBay Pharmaceuticals, Inc. (NYSE: NBY). He raised over $500 million for pharmaceutical and biotech companies.
Bernice R. Welles
Chief Executive Officer, Alquest Therapeutics, Inc. and Chief Medical Officer, Enject, Inc.
Bernice Welles has been Chief Executive Officer at Alquest Therapeutics, Inc. a neurodegenerative drug development company, since June, 2010, and Chief Medical Officer at Enject, Inc., a medical device company, since August 2009. Prior to that she was Vice President, Development at Diobex, Inc., a venture-backed biotechnology company, for four years. Dr. Welles has venture capital experience having been Venture Partner at MPM Capital, L.P. for four years and extensive pharmaceutical experience having been Vice President, Product Development and Senior Director and Director, Specialty Therapeutics Unit, Medical Affairs and Clinical Scientist, Medical Affairs at Genentech, Inc. for eight years.
Dr. Welles has a BA in Music from Brandeis University, a MS in Urban and Environmental Policy from Tufts University, a MD from Albany Medical College, and a M.B.A. from The Wharton School of Business, University of Pennsylvania. She has Medical Licensure, State of California, Diplomate, American Board of Internal Medicine and Diplomate, Endocrinology and Metabolism.
SCIENTIFIC ADVISORY BOARD
Vivian Hook, Ph.D.
Scientific Founder and Advisor of ALSP Inc. and Professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences, at the University of California, San Diego.
Professor Hook has over 20 years experience in the field of neuroprotease research and is the author of over 160 scientific articles and books on that subject. Dr. Hook previously was a Professor at the Buck Institute for Aging Research, Novato, California, Professor of Medicine and Neuroscience at the University of California, San Diego and a Professor at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. She was trained as a molecular pharmacologist and did post-doctoral studies at the National Institute of Health, Bethesda, Maryland, with Dr. Julius Axelrod, a Nobel Prize winner for his research in neuroscience. She holds a Ph.D. in Pharmacology from the University of California, San Francisco and a BA in Medical Physics from the University of California Berkeley.
Col. (Ret) Dallas Hack, M.D. Combat Casualty Care
U.S. Army Medical Research and Materiel Command
Since 2008, Col. Dallas Hack, MD was the director of the Combat Casualty Care Research Program and Chair, Joint Program Committee 6 (Combat Casualty Care), U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, coordinating leading edge-research focused on TBI. He also served as the Chair of Joint Technology Coordinating Group 6 of the Armed Services Biomedical Research Evaluation and Management (ASBREM) Committee. He has been awarded numerous medals, including the Bronze Star and Legion of Merit.
Dr. Hack graduated from Loma Linda University School of Medicine in 1976. After a rotating internship in Anesthesiology and a fellowship in Cardiology and Biomathematics, he worked in General Practice and Biomedical Engineering for 9 years, serving as Vice President of Engineering for a number of biomedical companies. He was recruited into active duty in September 1987, to modernize clinical research at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) completing a residency in General Preventive Medicine in 1995. He also has a MPH from Johns Hopkins, a Master of Strategic Studies from the U.S. Army War College, and a CPE from the Certifying Commission in Medical Management.
Steven Jacobsen, Ph.D.
Former Senior Project Director, Neuroscience iMed, AstraZeneca Neurosciences
Dr. Jacobsen left AstraZeneca, Neuroscience iMed after four years as Senior Project Director in June 2016. Prior to that he was Vice President, Head of Translational Biology Department at Proteostasis Therapeutics, a neurodegenerative drug development startup, for two years. He has extensive drug development experience in the pharmaceutical industry having been Senior Research Fellow, Neuroscience Translation at Pfizer Global R&D and Team Leader, Alzheimer’s disease-Modifying Program at Wyeth Research for fifteen years. Prior to that, Dr. Jacobsen was a Senior Scientist in CNS Biology, Lederle Labs, American Cyanamid. In addition, he is a consultant to several biotechnology startup organizations, and adjunct Associate Professor at Ohio State and New York University School of Medicine. Dr. Jacobsen obtained his BS in Chemistry and Physics and a MS in Biology at Seton Hall University and a Ph.D. in Molecular Genetics and Microbiology from New Jersey Medical School.
Kenneth Grabstein, Ph.D.
Kenneth Grabstein, Ph.D. is an Affiliate Professor of Chemical Engineering at University of Washington. He was formerly the Chief Scientific Officer and cofounder of Allozyne Inc. (2005-2014), the EVP and cofounder of Corixa Corp. (1994-2005), and Director of Immunology at Immunex Corp. (1982-1994). Dr. Grabstein received his Ph.D. in Immunology from U.C. Berkeley. He is currently a biotech industry consultant. He has built and led drug development teams in three companies with decades of experience in biologics drug discovery and product development in the biotech industry.